Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 32, Issue 27, 2014, Pages 3077-

  Kantarjian, Hagop ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCR ABL PROTEIN; CYTARABINE; IMATINIB; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

CHRONIC MYELOID LEUKEMIA; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; HUMAN; LETTER; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEM CELL TRANSPLANTATION; SURVIVAL; SURVIVAL RATE; TREATMENT RESPONSE; FEMALE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZAMIDES; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES;

EID: 84907220555     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.0904     Document Type: Letter

References (4)

1. Hehlmann R, Müller MC, Lauseker M, et al: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: Results from the randomized CML-Study IV. J Clin Oncol 32: 415-423, 2014
2. Hehlmann R, Lauseker M, Jung-Munkwitz S, et al: Tolerability-adapted imatinib 800 mg/d versus 400 mg/d versus 400 mg/d plus interferon-α in newly diagnosed chronic myeloid leukemia. J Clin Oncol 29: 1634-1642, 2011
3. Kantarjian HM, Larson RA, Cortés JE, et al: Current practices in the management of chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 13: 48-54, 2013
4. Falchi L, Kantarjian HM, Wang X, et al: Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors. Am J Hematol 88: 1024-1029, 2013